Vico Therapeutics Secures Nearly $71M in Series B Funding to Bolster Clinical Programs
VICO Therapeutics B.V., a clinical-stage genetic medicines company focusing on the development of novel therapies for severe neurological illnesses, has secured €65.8 million ($70.7 million) in Series B financing to advance lead clinical programs, Seroba announced on Monday, June 24, 2024.
Co-founded by Luc Dochez and Josh Mandel-Brehm, the startup’s latest financing round was spearheaded by Seroba., a Dubli... moreVico Therapeutics Secures Nearly $71M in Series B Funding to Bolster Clinical Programs
VICO Therapeutics B.V., a clinical-stage genetic medicines company focusing on the development of novel therapies for severe neurological illnesses, has secured €65.8 million ($70.7 million) in Series B financing to advance lead clinical programs, Seroba announced on Monday, June 24, 2024.
Co-founded by Luc Dochez and Josh Mandel-Brehm, the startup’s latest financing round was spearheaded by Seroba., a Dublin-headquartered life sciences venture capital firm, and a European venture capital firm, Kurma Partners.
